Allergic reaction to abciximab with atypical manifestations
Abciximab (ReoPro, Eli Lilly and Company, Indianapolis, Indiana) is an intravenous agent that had been approved for treatment of acute coronary syndrome undergoing coronary interventions. It is a chimeric monoclonal antibody fragment that binds to the glycoprotein IIb/IIIa receptor with a potential...
| Veröffentlicht in: | Journal of the Saudi Heart Association. - 1999. - 23(2011), 2 vom: 20. Apr., Seite 97-9 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | |
| Format: | Online-Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2011
|
| Zugriff auf das übergeordnete Werk: | Journal of the Saudi Heart Association |
| Schlagworte: | Journal Article Abciximab Allergic reaction Coronary intervention Glycoprotein IIb/IIIa inhibitor |
| Online verfügbar |
Volltext |